A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2031

Conditions

Moderately to Severely Active Ulcerative Colitis

Interventions

DRUG

Afimkibart

Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY